Sort   by:  
 Page size 
GenomicsAbiraterone resistance in prostate cancer cells
Abiraterone resistance in prostate cancer cells
PRJNA909815 | ENA
TranscriptomicsAbiraterone acetate and di-n-butyl phthalate (DBP) response in a human fetal testis xenograft bioassay
The goal of this study was to determine the effects of a well-characterized anti-androgen, abiraterone acetate, and a suspected human anti-androgen, di-n-butyl phthalate (DBP) on the androgenic function of human fetal testis. Human fetal testis was xenografted into the renal subcapsular space of cas...
ORGANISM(S): Homo sapiens 
2013-10-31 | E-GEOD-49244 | biostudies-arrayexpress
ProteomicsComparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer
Background: Abiraterone (Abi) is an androgen receptor signaling inhibitor that significantly improves patients' life expectancy in metastatic prostate cancer (PCa). Despite its beneficial effects, many patients have baseline or acquired resistance against Abi. Objective: To identify predictive seru...
ORGANISM(S): Homo sapiens (Human) 
2023-08-28 | PXD038697 | Pride
Abiraterone Fscn1 Prostate cancer Amacr Ctag1a Biomarker Klk2 
TranscriptomicsRNA-Seq analysis of prostate tumors with or without androgen receptor splice variant
Background. Androgen receptor splice variant-7 (AR-V7) is a truncated form of the androgen receptor protein which lacks the ligand-binding domain, the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of AR-V7 in circ...
ORGANISM(S): Homo sapiens 
2014-09-03 | E-GEOD-56701 | biostudies-arrayexpress
GenomicsRNA sequencing analysis of VCaP cells resistant to abiraterone
RNA sequencing analysis of VCaP cells resistant to abiraterone
PRJNA805247 | ENA
GenomicsSuper-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11
Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11
PRJNA1293943 | ENA
GenomicsPLK1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
PLK1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
PRJNA899498 | ENA
GenomicsSuper-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11 [CUT&Tag]
Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11 [CUT&Tag]
PRJNA1294880 | ENA
TranscriptomicsPLK1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
We found that synergy between the antiandrogen abiraterone and Plk1 inhibitors was completely independent of abiraterone's effects on AR signaling. To identify AR-independent effects of abiraterone we designed a comprehensive RNA seq experiment. This identified an AR-independent synergy-specific gen...
ORGANISM(S): Homo sapiens 
2023-01-24 | GSE217537 | GEO
TranscriptomicsAbiraterone resistance in prostate cancer cells
Castration resistant prostate cancer (CRPC) develops resistance to antiandrogens affecting Androgen Receptor (AR) signaling through a variety of mechanism. Because of this, the efficacy of androgen receptor targeted therapy remains limited for many patients with CRPC. We developed C42B-Abiraterone (...
ORGANISM(S): Homo sapiens 
2023-01-01 | GSE220467 | GEO
Sort   by:  
 Page size